secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2022-04-22T23:59:59+00:00
Accession:  0000950170-22-005981
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx director Aliski to exit at 2022 annual meeting; appoints Amrit Ray to board
--------------------------------------------------------------------------------

- William Aliski will not stand for re-election at 2022 annual meeting; departure for personal reasons, not disagreement.
- Amrit Ray, M.D., appointed as Class III director effective April 19, 2022; also joins Research and Development Committee.
- Ray is Chief Patient Officer at Biohaven (BHVN); previously senior roles at Pfizer and Johnson & Johnson.
- Ray granted 5,120 RSUs and option for 9,525 shares at $78.10 exercise price under standard director compensation.
- Board size set at ten directors: three Class I, three Class II, four Class III.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017022005981/0000950170-22-005981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017022005981/rare-20220418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer